Search Results
Your search for it matches 15588 pages
Showing 6101 - 6150Is Implicit Bias Contributing to Time Disparities in Goals-of-Care Conversations With Minority Patients?
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. It has been well...
Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers
Mansoor R. Mirza, MD, of Copenhagen University Hospital, and Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings, which showed that by adding veliparib to front-line carboplatin and paclitaxel and continuing it as monotherapy maintenance,...
ADMIRAL Study Finds Gilteritinib Effective Across Mutation Cohorts of Acute Myeloid Leukemia
The novel FLT3 inhibitor gilteritinib prolonged survival in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia (AML) across all mutation cohorts, including NPM1, DNMT3A, DNMT3A/NPM1, and WT1, with the greatest benefit seen in patients with NPM1 and DNMT3A co-mutations,...
Final Results of RESONATE Trial Show Long-Term Benefit of Ibrutinib in Relapsed or Refractory CLL
After 6 years of follow-up, extended treatment with ibrutinib showed sustained progression-free survival benefit and depth of response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), including those with high-risk genomic features,...
ESMO 2019: First-Line Immunotherapy Shows Clinical Benefit in Advanced Hepatocellular Carcinoma
New data have shown a trend toward clinically meaningful improvements in survival and response rates and a favorable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC). The data, reported by Yau et al at the European...
ESMO 2019: Men With Prostate Cancer May Avoid Postoperative Radiotherapy, Study Finds
Men with prostate cancer may be spared radiotherapy after surgery, according to late-breaking results of the RADICALS-RT trial presented by Parker et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA49_PR). The study answers a long-standing question about whether...
FDA Announces Voluntary Recall of Certain Ranitidine Capsules
This week, the U.S. Food and Drug Administration (FDA) alerted health-care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc, used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine...
Ned Sharpless, MD, Testifies Before House Subcommittee on FDA Investigation of Vaping Illnesses and Regulation of E-Cigarettes
Earlier this week, Acting Commissioner of the U.S. Food and Drug Administration (FDA) Ned Sharpless, MD, testified before the U.S. House Energy and Commerce Subcommittee on the FDA’s planned regulation of electronic nicotine delivery systems and investigation of vaping illnesses. His remarks are...
HPV-Positive Oropharyngeal Cancer Burden Rising Among White Men in the United States
White men older than age 65 will have the greatest burden of oropharyngeal cancer by the year 2030, according to Maura L. Gillison, MD, PhD, Professor and Endowed Chair at MD Anderson Cancer Center in Houston. But there is some good news, she said at the 2019 Winship Cancer Institute of Emory...
Diabetes and Cancer: Researchers Link Hyperglycemia to DNA Damage
Hyperglycemia may induce DNA damage and inhibit DNA repair, which may explain why individuals with diabetes may have an increased risk for developing cancer, according to a researcher from City of Hope, Duarte, California, who presented these findings at the American Chemical Society (ACS) Fall...
Raising the Quality of Cancer Care Globally
ASCO’s global vision is, “A world where cancer is prevented or cured, and every survivor is healthy.” In its work toward achieving this vision, the Society offers a robust portfolio of programs that are continually expanding around the world that improve access to quality cancer care, support...
International Innovation Grants Expand Global Reach of Training and Care
Physicians and nurses in low- and middle-income countries (LMICs) have fewer training opportunities, limited medical and educational resources, and insufficient palliative care options for their patients,1 all while these regions are leading the world in new cases of cancer diagnosis.2 An emerging...
The Role of Primary Care Physicians in Cancer Care
As our aging population increases, so does the demand for oncology services; however, as ASCO and other organizations have pointed out, a workforce shortage of oncology care specialists looms in the not-so-distant future. Given the growing need for care models that meet this demand, a better...
Update on Treatments Under Study for Chronic Lymphocytic Leukemia
The ASCO Post has offered comprehensive coverage of the 2019 ASCO Annual Meeting. To complement this news coverage, here are featured clinical trials of several treatments in chronic lymphocytic leukemia (CLL). They focus on the monoclonal antibody obinutuzumab in combination therapy in the CLL14...
Investigating the Inflammatory Mechanisms That May Be Causing Prostate Cancer in World Trade Center First Responders
The terrorist attacks on September 11, 2001*, on the World Trade Center in New York City resulted in the deaths of more than 2,700 people.1 Nearly 2 decades later, that number may soon be exceeded by the more than 2,000 deaths—and climbing—of first responders to the attack, including firefighters,...
Differences By Sex in Lung Cancer Incidence and Mortality: What Is Known, and What Does It Mean?
The finding that women have a higher incidence of lung cancer than men of the same age and with the same smoking history was unexpected when it first emerged from studies in the 1990s. Just as unexpected was a subsequent finding. Even with their higher risk, women have a lower mortality and higher...
How Ultrahigh-Dose Radiation Therapy, Interferon, and CAR T Cells May Boost Immunotherapy Effectiveness
This past June, the University of Pennsylvania established the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation to study the role interferon and pattern recognition receptor signaling transduction pathways play in modulating the immune system’s ability to recognize and...
The Fight Against Breast Cancer Illustrates the Health-Care Challenges of Women in Poverty
"Of all the forms of inequality, injustice in health is the most shocking and the most inhumane….” —Dr. Martin Luther King, Jr Progress has been made in expanding access to health care for low-income populations, but the quality of care still lags behind and can result in less successful outcomes...
CATNON Trial Shows Concurrent Temozolomide May Offer Benefit in IDH-Mutant Anaplastic Glioma
Concurrent temozolomide treatment during radiotherapy did not increase overall survival in patients with anaplastic gliomas without 1p/19q co-deletion, according to data from the second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial.1 However, benefit ...
Avelumab Plus Axitinib in Advanced Renal Cell Carcinoma
Earlier this year, avelumab was approved for use in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma.1,2 Supporting Efficacy Data Approval was based on findings in the open-label phase III -JAVELIN Renal 101 trial (ClinicalTrials.gov identifier...
Finding a New Focus After Cancer
In the early fall of 2015, my daughter and I were on our way to our favorite nail salon to get picture-perfect ready for a gala later that evening at Lincoln Center for the Performing Arts in New York, when I got a call from my gynecologist saying I had “flunked my Pap test.” The Pap smear showed...
Ramucirumab in Hepatocellular Carcinoma
Earlier this year, ramucirumab was approved as a single agent for hepatocellular carcinoma in patients who have an alpha-fetoprotein (AFP) level ≥ 400 ng/mL and have been previously treated with sorafenib.1,2 Supporting Efficacy Data Approval was based on findings in the double-blind phase III...
Prevent Cancer Foundation Awards $250,000 in Community Grants
Through its community grants program, the Prevent Cancer Foundation is supporting 10 projects that are focused on increasing cancer prevention and early detection in communities across the United States, from Honolulu to Baltimore. The projects were selected through a competitive grants process,...
Personalizing Medicine
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
AACR Disparities: Uninsured/Underinsured, Lower-Income, and/or Minority Patients More Likely to Receive Cancer Diagnosis After ED Visit
Medicare patients from lower socioeconomic groups and several ethnic minority groups were more likely to be diagnosed with cancer following an emergency department visit, according to results of a study presented at the 12th American Association for Cancer Research Conference on The Science of...
Origin and Taxonomy of Mucinous Ovarian Cancer
An international study has revealed the origin of mucinous ovarian cancer, confirming that unlike other types of ovarian cancer, this cancer arises from benign and borderline precursors at the ovaries and are not extraovarian metastases. These findings were published by Cheasley et al in Nature...
Addition of Induction Gemcitabine/Cisplatin to Chemoradiotherapy in Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The New England Journal of Medicine, Zhang et al found that the addition of gemcitabine/cisplatin induction chemotherapy to standard platinum-based chemoradiotherapy improved recurrence-free survival vs chemoradiotherapy alone in locoregionally advanced...
AACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. Cities
According to the American Cancer Society, excluding skin cancers, colorectal cancer is the third most common cancer in both men and women in the United States and the second most common cause of cancer deaths. This year, it is expected that more than 51,000 people will die of the malignancy....
FDA Approves Cologuard for Persons Aged 45 and Older at Average Risk for Colorectal Cancer
Today, the U.S. Food and Drug Administration (FDA) approved the noninvasive colorectal cancer screening test Cologuard for eligible average-risk individuals aged 45 years and older, expanding on its previous indication for those aged 50 years and older. Cologuard is a stool DNA-based colorectal...
Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple Myeloma
The monoclonal antibody daratumumab has been widely embraced for the treatment of multiple myeloma, but for newly diagnosed patients, its benefit has been proved only in some patients, according to Craig Hofmeister, MD, MPH, Associate Professor of Medicine at the Winship Cancer Institute of Emory...
Two Studies Show Variation in Effectiveness of Mammography Across Populations
Two recent studies showed varying degrees of the effectiveness of mammography in different populations. In a report published in Radiology, Gao et al showed that in men at high risk for breast cancer, screening mammography may be able to increase the rate of detection of early-stage disease....
Flaxseed
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on flaxseed because...
ESMO 2019 Award Winners Announced
The European Society for Medical Oncology (ESMO) has revealed the 2019 winners of its annual awards. The four distinguished clinicians and scientists will be presented during the ESMO 2019 Congress in Barcelona: Eric Van Cutsem, MD, PhD; Angelo Di Leo, MD, PhD; Cristiana Sessa, MD; and Charles...
Two Fred Hutch Scientists Receive Fellowships for Prostate Cancer Research
Two early-career scientists at Fred Hutchinson Cancer Research Center—Alexandra Corella and Sander Frank, PhD—have received grants to further their prostate cancer research. Ms. Corella, a graduate research assistant, won a $25,000, 1-year fellowship from the Ford Foundation Fellowship Programs,...
The Lasker Foundation Names Recipients of the 2019 Awards for Medical Research and Public Service
Earlier this month, The Lasker Foundation announced the recipients of its 2019 Lasker Awards for clinical and basic research and public service. Lasker~DeBakey Clinical Medical Research Award H. Michael Shepard, PhD,formerly of Genentech, Dennis J. Slamon, MD, PhD, of the University of California,...
Patient-Centered Initiatives at the FDA
OCE Insights is a periodic column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this first installment, Vishal Bhatnagar, MD, Acting Associate Director of Patient Outcomes; Bellinda King-Kallimanis, PhD, Senior...
Adjuvant Treatment With Ado-trastuzumab Emtansine in HER2-Positive Early Breast Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Earlier this year, ado-trastuzumab emtansine (T-DM1) was...
Canadian Cancer Organizations Team Up to Focus on New Approach to Metastatic Breast Cancer
At a press conference at McGill University, Stand Up To Cancer Canada (SU2C Canada), the Canadian Cancer Society (CCS), and the Canadian Institutes of Health Research (CIHR) announced the launch of the SU2C Canada Metastatic Breast Cancer Dream Team to pursue the development of a new drug...
Current Controversies in Lymphoma: From the Role of Liquid Biopsy to Ways to Improve Upon Standard Chemotherapy
Two topics that hematologists are currently grappling with were addressed at the 2019 Debates and Didactics Conference in Sea Island, Georgia, sponsored by Emory University Winship Cancer Institute, by Editor-in-Chief of The ASCO Post, James O. Armitage, MD, FASCO.1 They focus on the emerging role ...
Suboptimal Insurance Linked to Worse Survival Outcomes in Positive Clinical Trials
Findings from a recent SWOG study could cast doubt on the generalizability of treatment effects observed in positive clinical trials, especially among underinsured patients. According to data presented at the 2019 ASCO Quality Care Symposium,1 patients with Medicaid or no insurance had no observed...
Tumor Mutational Burden Disappoints as Biomarker for Treatment Response in Exploratory Analyses of Nonsquamous NSCLC
Tumor mutational burden failed to prove effective as a biomarker for response to chemotherapy plus checkpoint inhibitor or chemotherapy alone as first-line treatment for nonsquamous non–small cell lung cancer (NSCLC) in two different exploratory analyses of KEYNOTE trials.1,2 In both analyses,...
Benefits Reported With Addition of Isatuximab to Pomalidomide and Dexamethasone in Resistant Multiple Myeloma
In patients with relapsed or refractory multiple myeloma, isatuximab in combination with pomalidomide and low-dose dexamethasone nearly doubled progression-free survival when compared with pomalidomide and dexamethasone alone, with a manageable safety profile, according to data from a phase III...
AACR Cancer Progress Report 2019 Released
Today, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2019, which highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring improvements in public health and innovations across the spectrum...
ASTRO 2019: Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC: Analysis of the PACIFIC Trial
Andreas Rimner, MD, of Memorial Sloan Kettering Cancer Center, presented an update of the landmark PACIFIC trial at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO) (Abstract LBA-6). In earlier reports from the randomized phase III trial, Antonia et al had evaluated...
Targeting an Important Tumor Vulnerability With Maintenance Olaparib in Germline BRCA-Mutated Pancreatic Cancer
In the POLO trial, which is discussed in this issue of The ASCO Post, Golan and colleagues evaluated the potential benefit of maintenance olaparib after disease stability or response to a minimum of 4 months of platinum-based chemotherapy in patients with metastatic pancreatic cancer and a...
ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy
Findings from the randomized phase III NRG Oncology/RTOG 9601 trial were initially reported in 2017, and showed that the addition of 2 years of antiandrogen therapy to postsurgical radiation treatment for men with recurrent prostate cancer increased their long-term overall survival rate. That study ...
ASTRO 2019: Machine-Learning Model May Accurately Predict Radiation Side Effects in Patients With Head and Neck Cancers
A study by Reddy et al investigating the use of a machine-learning model to predict which patients with head and neck cancer being treated with radiation may experience significant weight loss, feeding tube placement, and unplanned hospitalization has found that the model accurately identified the...
FDA Issues Drug Safety Communication on Lung Inflammation Due to Treatment With CDK4/6 Inhibitors
On September 13, the U.S. Food and Drug Administration (FDA) issued a drug safety communication warning that palbociclib, ribociclib, and abemaciclib—used to treat some patients with advanced breast cancer—may cause rare but severe inflammation of the lungs. The agency approved new warnings about...
Conundrums in Managing Cancer-Associated Thrombosis
Although there may be a clear role for prophylactic anticoagulation in hospitalized patients and those undergoing surgery, indication for prophylactic anticoagulation for patients with cancer seen in the ambulatory setting has yet to emerge. Until clinical trial data on prophylactic...
ASTRO 2019: Effect of Closure of Women’s Health Clinics From 2010 to 2013 on Cervical Cancer Screening and Detection
Following the closure of nearly 100 women’s health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer; more women were diagnosed with advanced stages of the disease; and disease mortality rates rose. Findings from a new analysis combining several...
